May 01, 2020
Congressional Investigations Alert
Congressional Investigations Alert
The U.S. House of Representatives’ new Select Subcommittee on the Coronavirus Crisis has the potential to shift the center of public oversight activity from the Treasury Department to Congress.
With Congress continuing to pass additional stimulus to supplement the more than $2 trillion under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), the U.S. House of Representatives’ new Select Subcommittee on the Coronavirus Crisis has the potential to shift the center of public oversight activity from the Treasury Department to Congress.
Created on April 23 by the House’s passage of a bill sponsored by House Rules Committee Chairman Jim McGovern (D-MA), this subcommittee of the Oversight and Reform Committee is chaired by Minority Whip James Clyburn (D-S.C.), enjoys the power to subpoena documents and depose witnesses, and will start with a $2M budget to undertake its work.
This Committee’s creation suggests that a number of CARES Act fund recipients may be facing their most visible oversight from a congressional inquiry rather than from an agency enforcement proceeding. Speaker Pelosi explained that the panel’s goal is to ensure that the funds that “Congress has dedicated to this battle—and any additional funds Congress provides in future legislation—are spent wisely and effectively.” The subcommittee is intended to follow the mold of the World War II-era Truman Committee, which investigated profiteering, price gouging, and other abuses related to government defense funding. It will be comprised of seven Democrats, including three chairs of existing House committees: Oversight Committee Chair Carolyn Maloney (D-NY), Financial Services Committee Chair Maxine Waters (D-CA), Small Business Committee Chair Nydia Velazquez (D-NY), and Reps. Jamie Raskin (D-MD), Bill Foster (D-IL), and Andy Kim (D-NJ), as well as up to five Republicans who have not yet been named.
As outlined in a previous alert, businesses receiving funds through the CARES Act will be facing careful oversight scrutiny built into the legislation, including through the new office of Special Inspector General for Pandemic Recovery (SIGPR), which is tasked with conducting, supervising, and coordinating audits and investigations of the making, purchase, management, and sale of loans, loan guarantees, and other investments made under the Cares Act and which is required to file quarterly reports with Congress that provide the details of all loans, loan guarantees, and other investments. The legislation has provided $25M for the SIGPR to perform its work.
The CARES Act also provides for oversight to reside in three other entities:
It is yet to be seen how the new House Select Subcommittee will undertake its charge in light of social distancing. One method recently employed by the Senate Commerce Committee is a “paper hearing” in which opening statements and testimony were submitted and posted on the committee’s website and witnesses were asked to submit written answers to members’ questions within 96 business hours. Subjects of oversight should be prepared for responding to such non-traditional requests in light of the current public health protocols.
Regardless of how congressional investigators proceed, CARES Act funding recipients can take a number of steps now to help position themselves well to respond if such inquiries follow:
CARES Act funding recipients may receive inquiries from any of these congressional or agency oversight authorities, and response strategies will vary substantially. Nixon Peabody’s experienced Congressional Investigations Team is prepared to advise clients in handling such requests.
The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.
Life Sciences Alert | 08.27.20
Government Investigations & White Collar Defense Alert | 06.05.20
Government Investigations & White Collar Defense Alert | 05.08.20
Public Finance Alert | 05.07.20
Commercial Litigation Alert | 05.06.20
Webinar Recording | 04.28.20
Affordable Housing Alert | 03.26.20
Franchise Alert | 03.26.20
07.21.20 | Webinar
05.14.20 | Webinar